Exonics Therapeutics Stock

exonicstx.comBioTechFounded: 2017Funding to Date: $45MM

Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time treatment that would make a permanent correction of the mutation that causes Duchenne by identifying and correcting exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers, enabling patients to improve their lives and have a lifelong benefit.

Register for Details

For more details on financing and valuation for Exonics Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

John Ripple
Chief Executive Officer & Board Member
Jesper Gromada Ph.D
Chief Scientific Officer
Eric Olson Ph.D
Founder, Chief Science Advisor & Board Observer
David Goeddel Ph.D
Chairman

Board Members

David Goeddel Ph.D
Eric Olson Ph.D
JeenJoo Kang Ph.D
The Column Group
John Edwards
John Ripple

Other companies like Exonics Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Exonics Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company, secured $40m in Series A financing. The Column Group (TCG), a science-driven venture capital firm, made the investment. In conjunction with the funding, TCG’s David Goeddel, Ph.D., managing partner, and JJ Kang, Ph.D., principal, will be joining the company’s board of directors. The company intends to use …